"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."

Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

DISCOVERY 1TO3 Trial

05/09/2018 -  

60 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Published

Designed to:

  • Assess endothelial coverage at 1, 2 and 3 months by OFDI in patients with multivessel disease scheduled for staged PCI procedure
  • Provide a "look" in the artery with OFDI after implantation of Ultimaster
  • Investigate possibility for shorter DAPT by generating relevant clinical scientific data

 

Study Design

  • Single arm
  • 60 patients with planned staged PCI at 1M/3M
  • Total of 6 sites
  • 3 countries: France, Germany, Netherlands
  • Primary endpoint: OFDI assessed % stent strut coverage at 3M post procedure


Hypothesis: < 20% uncovered struts at 3M post procedure

DISCOVERY 1TO3 - Study Design

Primary endpoint was met with strut coverage of 95% achieved by 3 months

  • Patient cohort included complex cases and lesions
discovery_1_TO_3_Image2.png

Data are mean±SD

  • The mean (SD) number of diseased vessels per patient was 2.2 (0.5), and the mean (SD) number of lesions detected was 3.2 (1.6) 
  • The mean (SD) total number of lesions treated per patient was 2.1 (0.7) 
  • Good clinical outcomes were observed between 1 month and 1 year, with no cases of death, MI, TVR, or ST reported 
    • Incidences of TLR and TLF between 1 month and 1 year were 3.4% for both 
  • There were no significant differences in baseline patient characteristics, lesion characteristics, or procedural characteristics between the two groups 
    • 69.8% of procedures that used Ultimaster were performed using transradial access, and the overall procedure success rate was 97.8% 
  • At 5 years, there was a trend towards better clinical outcomes with Ultimaster than with Xience (statistical significance not met) 
    • Any death: 9.3% vs 10.8% (p=0.60) 
    • Any MI: 3.1% vs 5.6% (p=0.19) 
    • Stent thrombosis: 0.9% vs 1.7% (p=0.43)

References:

MI, myocardial infarction; SD, standard deviation; ST, stent thrombosis; TLF, target lesion failure; TLR, target lesion revascularisation;
TVR, target vessel revascularisation.
MVD, multivessel disease; SD, standard deviation.
Chevalier B et al. Circ Cardiovasc Interv 2017;10. pii: e004801:doi:10.1161/CIRCINTERVENTIONS.116.004801;
Chevalier B et al. Presented at EuroPCR 2017, abstract OP0698;
Iniguez-Romo A et al. Presented at EuroPCR 2018, abstract LBT8727.
Data on file at Terumo Europe.